Electronic health record data from 17 US health systems between 1/1/2021-12/31/2024 were analyzed to determine the prevalence of Lp(a) testing among adults with ASCVD and changes in LDL-C management in those who are identified to have elevated Lp(a) levels.
N. Shah, P. Shrader, N. Freeman et al.· European Heart Journal· 0 citations
Among patients with IPF, antifibrotic dose reductions and discontinuations were common, likely due to poor drug tolerability, and disease progression occurred in a substantial proportion of patients in both cohorts, regardless of antifibrotic dosing strategy, highlighting the ongoing need for more effective and better-...
A. Swaminathan, Susanna R. Stevens, Pooja Chopra et al.· Chest· 0 citations
BACKGROUND
Although the effectiveness of Lp(a) (lipoprotein[a])-lowering therapies remains under study, lipid guidelines now recommend Lp(a) testing in all adults to identify individuals who need more aggressive risk factor modification. Therefore, we evaluate contemporary patterns of Lp(a) testing and the impact of te...
Nishant P. Shah, P. Shrader, Nikki L. B. Freeman et al.· Circulation. Population heal...· 0 citations
In ASCVD patients, LDL-C levels plateau well above guideline targets following an initial decline, and proactive, system-level monitoring and timely intervention are urgently needed to reduce cumulative above-goal LDL-C exposure.
S. Shoji, P. Shrader, Nikki L. B. Freeman et al.· JACC: Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.